Disclosed are compounds of Formula (I):
or a salt thereof, wherein: Z is CR
6
R
6
or C═O; Ring A is:
and R
1
, R
2
, R
3
, R
4
, R
5
, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
The present invention relates to isoquinolinone derivatives of formula (I):
wherein are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Compounds having the structure (or their salts):
are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. The compounds can be formulated together with pharmaceutically acceptable diluents or carriers or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.
Heterocyclic Compounds Which Modulate The CB2 Receptor
申请人:Bartolozzi Alessandra
公开号:US20110312944A1
公开(公告)日:2011-12-22
Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA]
申请人:Phenex Pharmaceuticals AG
公开号:US20150175562A1
公开(公告)日:2015-06-25
The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1′), (100), (100′), (200) and (200′) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.